Resultado de búsqueda
Hace 11 horas · The global market size for hyperglycemia treatment is estimated to reach USD USD 1,596 Million by 2033. According to the forecast, the insulin therapy segment is expected to grow by 6% CAGR between 2023 and 2033. The oral route of administration hyperglycemia treatment market accounted for 45% of the total market value by the end of 2023.
Hace 11 horas · Finding stocks capable of outperforming the vaunted S&P 500 over a multiyear period is incredibly difficult. Pharma stocks, in particular, are known for outperforming one year and lagging behind ...
Hace 11 horas · It’s not too late to get your tickets, The Royal Bath and West Show throws open its gates to visitors on today with a packed three-day programme ahead. The show runs from 30th May until 1st June ...
Hace 11 horas · The New Multi-Modal Hydrogen Refueling Stations will have Capacity to Fuel as many as 200 Heavy-Duty Trucks or 2,000 Light-Duty Vehicles Per Day. LEHIGH VALLEY, Pa., May 29, 2024 /PRNewswire/ — Air Products (NYSE:APD) today announced it intends to build a network of permanent, commercial-scale, multi-modal hydrogen refueling stations stretching from Northern California to Southern California.
Hace 11 horas · Pomerleau and Alstef Canada selected to help usher in next era of connectivity and convenience from the heart of downtown Toronto. TORONTO, May 29, 2024 /CNW/ – As the latest step in a more connected Toronto, Billy Bishop Toronto City Airport is pleased to announce the selection of Pomerleau as the construction management firm and Alstef Canada as the baggage handling system provider for ...
Hace 11 horas · Thursday, May 30th, 2024 at PR Newswire. HIGH POINT, N.C., May 29, 2024 /PRNewswire/ — Advanced Fraud Solutions (AFS), a leader in fraud prevention services, has announced a strategic partnership with Tru Treasury, the premier provider of treasury management solutions. This collaboration introduces Positive Pay by AFS, an advanced fraud ...
Hace 3 horas · Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name for oncology indications: Carteyva ®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company).
